3 active not recruiting, 1 completed, 1 no longer available. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 2, Completed 1 |
| Phase 2 | 3 | Active not recruiting 3 |
Follow Melanoma Recurrent: new trials by email Literature Review of Melanoma Recurrent trials Research Report on Melanoma Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution) - Melanoma Metastatic, Melanoma of Skin | Phase 1 / Phase 2 | Active not recruiting | BioInvent International AB | 35 | 2024-12-11 | 2026-10-02 |
| Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS) Pembrolizumab - Melanoma Metastatic, Melanoma Recurrent | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 29 | 2021-12-10 | 2026-01-29 |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors ST101, Temozolomide, Radiation - Glioblastoma, Melanoma Stage IV | Phase 1 / Phase 2 | Active not recruiting | Sapience Therapeutics | 125 | 2020-07-01 | 2026-02-09 |
| Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma Vigil, Pembrolizumab - Melanoma Recurrent, Malignant Melanoma | Phase 1 | Completed | Gradalis, Inc. | 2 | 2015-10-01 | 2017-09-27 |
| Expanded Access for Pembrolizumab (MK-3475) pembrolizumab - Melanoma (Skin), Melanoma Recurrent | No longer available | Center Trials & Treatment | 2018-01-10 |
Melanoma (5) · Glioblastoma (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Glioma (1) · Neoplasm Metastasis (1) · Prostatic Neoplasms (1) · Uveal Melanoma (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Nerve Tissue (5) · Neuroectodermal Tumors (5) · Neuroendocrine Tumors (5) · Nevi and Melanomas (5) · Skin Diseases (5) · Skin Neoplasms (5) · Skin and Connective Tissue Diseases (5) · Astrocytoma (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Neuroepithelial (2) · Brain Diseases (1)
pembrolizumab (4) · FANG vaccine (1) · Immune Checkpoint Inhibitors (1) · Ipilimumab (1) · Radiation (1) · Solutions (1) · Temozolomide (1)
BioInvent International AB (1) · Center Trials & Treatment (1) · Gradalis, Inc. (1) · Instituto do Cancer do Estado de São Paulo (1) · Sapience Therapeutics (1)
United Kingdom (2) · United States (2) · Belarus (1) · Brazil (1) · Germany (1) · Hong Kong (1) · Spain (1) · Tajikistan (1) · Uzbekistan (1)
Abi Vainstein-Haras, MD (1) · Luisa Manning, MD (1)